Applicant: John David Fraser et al. Attorney's Docket No.: 11752-012US1 / SHR 504430USPR

Serial No.: Not Yet Assigned

Filed : September 25, 2006

: 3 of 7 Page

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## Listing of Claims:

1. (Original) A method of isolating IgA present in a sample, the method comprising at least the steps of:

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to IgA to form a complex;

Separating the complex; and,

Releasing IgA from the complex.

2. (Original) A method of isolating C5 present in a sample, the method comprising at least the steps of:

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to C5 to form a complex;

Separating the complex; and,

Releasing C5 from the complex.

3. (Original) A method for isolating IgA from a sample, the method comprising at least the steps of:

Providing a matrix to which a SET1 protein or functional equivalent is bound;

Providing a sample;

Bringing said matrix and said sample into contact for a period sufficient to allow

SET1 or functional equivalent thereof to bind to IgA present in the sample; and,

Releasing IgA from the matrix.

4. (Original) A method as claimed in claim 3 wherein the method further comprises the step of collecting the IgA released.

Applicant: John David Fraser et al.

Serial No.: Not Yet Assigned

Attorney's Docket No.: 11752-012US1 / SHR
504430USPR

Serial No.: Not Yet Assigned Filed: September 25, 2006

Page : 4 of 7

5. (Currently amended) A method as claimed in elaims 3 or 4 claim 3 wherein the matrix is in the form of a column over which the sample is passed.

- 6. (Currently amended) A method as claimed in any one of claims 3 to 5 claim 3 wherein the method further comprises the step of washing contaminants present in the sample from the matrix prior to release of IgA.
- 7. (Currently amended) A method as claimed in any one of claims 3 to 6 claim 3 wherein the matrix is Sepharose.
- 8. (Currently amended) A method as claimed in any one of claims 3 to 7 claim 3 wherein the sample is milk.
- 9. (Currently amended) A method as claimed in any one of claims 3 to 7 claim 3 wherein the sample is colostrum.
- 10. (Currently amended) A method as claimed in any one of claims 3 to 7 claim 3 wherein the sample is serum.
- 11. (Currently amended) A method as claimed in any one of claims 3 to 7 claim 3 wherein the method further comprises the step of determining the quantity of IgA present in the sample.
- 12. (Currently amended) A method as claimed in any one of claims 3 to 11 claim 3 wherein IgA is released from the matrix using a 100mM glycine buffer at pH 3.0.
- 13. (Original) A method for isolating C5 from a sample, the method comprising at least the steps of:

Providing a matrix to which a SET1 protein or functional equivalent is bound;

Providing a sample;

Bringing said matrix and said sample into contact for a period sufficient to allow SET1 or functional equivalent thereof to bind toC5 present in the sample; and,

Releasing C5 from the matrix.

- 14. (Original) A method as claimed in claim 13 wherein the method further comprises the step of collecting the C5 released.
- 15. (Currently amended) A method as claimed in claim 13 or 14 wherein the matrix is in the form of a column over which the sample is passed.
- 16. (Currently amended) A method as claimed in any one of claims 13 to 15 claim 13 wherein the method further comprises the step of washing contaminants present in the sample from the matrix prior to release of C5.

Applicant: John David Fraser et al. Attorney's Docket No.: 11752-012US1 / SHR Serial No.: Not Yet Assigned 504430USPR

Serial No.: Not Yet Assigned Filed: September 25, 2006

Page : 5 of 7

17. (Currently amended) A method as claimed in any one of claims 13 to 16 claim 13 wherein the matrix is Sepharose.

- 18. (Currently amended) A method as claimed in any one of claims 13 to 17 claim 13 wherein the sample is milk.
- 19. (Currently amended) A method as claimed in any one of claims 13 to 17 claim 13 wherein the sample is colostrum.
- 20. (Currently amended) A method as claimed in any one of claims 13 to 17 claim 13 wherein the sample is serum.
- 21. (Currently amended) A method as claimed in any one of claims 13 to 20 claim 13 wherein the method further comprises the step of determining the quantity of C5 present in the sample.
- 22. (Currently amended) A method as claimed in any one of claims 13 to 21 claim 13 wherein C5 is released in low pH buffer such as 50mM acetate pH 3.5.
- 23. (Original) A method of detecting IgA in a sample, the method comprising at least the steps of:

Contacting a sample with SET1 or functional equivalent thereof for a period sufficient to allow SET1 or functional equivalent thereof to bind to IgA; and,

Detecting bound SET1 or functional equivalent thereof.

24. (Original) A method of detecting C5 in a sample, the method comprising at least the steps of:

Contacting a sample with SET1 or functional equivalent thereof for a period sufficient to allow SET1 or functional equivalent thereof to bind to C5; and,

Detecting bound SET1 or functional equivalent thereof.

- 25. (Currently amended) A method as claimed in claim 23 or 24 wherein the method further includes the step of determining or quantifying the level of bound SET1.
- 26. (Original) A method as claimed in claim 23 wherein the method is conducted for the purpose of diagnosing IgA abnormality in a subject.
- 27. (Original) A method as claimed in claim 24 wherein the method is conducted for the purpose of diagnosing C5 abnormality in a subject.
- 28. (Currently amended) A method as claimed in any one of claims 23 to 26 claim 23 wherein the subject is a mammal.
  - 29. (Original) A method as claimed in claim 28 wherein the mammal is a human.

Applicant: John David Fraser et al. Attorney's Docket No.: 11752-012US1 / SHR 504430USPR

Serial No.: Not Yet Assigned : September 25, 2006

Filed

Page : 6 of 7

30. (Original) A method of removing IgA from a sample, the method comprising at least the steps of:

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to IgA to form a complex; and,

Separating the complex from the sample.

31. (Original) A method of removing C5 from a sample, the method comprising at least the steps of:

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to C5 to form a complex; and,

Separating the complex from the sample.

- 32. (Original) An isolated protein having the amino acid sequence SEQ ID NO: 6 or SEQ ID NO: 7.
- 33. (Original) An isolated nucleic acid encoding a protein of SEQ ID NO: 6 or SEQ ID NO: 7.
- 34. (Original) An isolated nucleic acid as claimed in claim 30 wherein the nucleic acid sequence is that represented by SEO ID NO: 12 or SEO ID NO: 13.
- 35. (Original) A kit for the detection, isolation, and/or removal of IgA and/or C5 in a sample, the kit comprising at least SET1 or a functional equivalent thereof.
- 36. (New) A method as claimed in claim 24 wherein the method further includes the step of determining or quantifying the level of bound SET1.
  - 37. (New) A method as claimed in claim 24 wherein the subject is a mammal.